Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 3.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions
: MedicationRecommendationExample1 - TTL Representation
Raw ttl | Download
@prefix fhir: <http://hl7.org/fhir/> .
@prefix loinc: <https://loinc.org/rdf/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:Task ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "MedicationRecommendationExample1"] ; #
fhir:meta [
( fhir:profile [
fhir:v "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/medication-recommendation"^^xsd:anyURI ;
fhir:link <http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/medication-recommendation> ] )
] ; #
fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Task MedicationRecommendationExample1</b></p><a name=\"MedicationRecommendationExample1\"> </a><a name=\"hcMedicationRecommendationExample1\"> </a><a name=\"MedicationRecommendationExample1-en-US\"> </a><p><b>status</b>: Requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: <span title=\"Codes:{http://loinc.org LA26421-0}\">Consider alternative medication</span></p><p><b>description</b>: Patients positive for this allele should not be treated with CBZ, unless the benefits clearly outweigh the risk. Therapy should be discontinued immediately if symptoms of SJS or TEN develop. Alternative medication should be used as first line therapy. Consideration in the choice for alternative medications should be given to potential cross-reactivity with structurally similar aromatic antiepileptic drugs such as oxcarbazepine, phenytoin, fosphenytoin and lamotrigine, which can also moderately increase risk for SJS/TEN in association with HLA-B*15:02 positivity.</p><p><b>for</b>: <a href=\"Patient-CGPatientExample01.html\">Adam B. Everyman Male, DoB: 1951-01-20 ( Medical Record Number: m123 (use: usual, ))</a></p><p><b>reasonReference</b>: <a href=\"Observation-TherapeuticImplicationExample1.html\">Observation Therapeutic Implication</a></p></div>"
] ; #
fhir:status [ fhir:v "requested"] ; #
fhir:intent [ fhir:v "proposal"] ; #
fhir:code [
( fhir:coding [
a loinc:LA26421-0 ;
fhir:system [ fhir:v "http://loinc.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "LA26421-0" ] ] )
] ; #
fhir:description [ fhir:v "Patients positive for this allele should not be treated with CBZ, unless the benefits clearly outweigh the risk. Therapy should be discontinued immediately if symptoms of SJS or TEN develop. Alternative medication should be used as first line therapy. Consideration in the choice for alternative medications should be given to potential cross-reactivity with structurally similar aromatic antiepileptic drugs such as oxcarbazepine, phenytoin, fosphenytoin and lamotrigine, which can also moderately increase risk for SJS/TEN in association with HLA-B*15:02 positivity."] ; #
fhir:for [
fhir:reference [ fhir:v "Patient/CGPatientExample01" ]
] ; #
fhir:reasonReference [
fhir:reference [ fhir:v "Observation/TherapeuticImplicationExample1" ]
] . #
|
Propose a change